All
23 April 2025
Animab Secures EUR 10 Million in Series B Financing to Launch Nanoprotec® in Europe and Expand Pipeline
•All current investors participated in the round led by AIF,PMV and QBIC III, alongside new investor Anacura.
•Funds will support EU commercialization of...
18 March 2025
MaaT Pharma Announces Positive Outcomes from Final DSMB Meeting for Pivotal Phase 3 Clinical Trial Evaluating MaaT013 in Acute Graft-versus-Host Disease
MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated...
24 February 2025
Citryll demonstrates a broader therapeutic potential for cit-013 in the treatment of inflammatory disorders
Breakthrough study published in Frontiers in Immunology demonstrates CIT-013’s effectiveness against additional types of extracellular traps, expanding potential therapeutic...
21 February 2025
SeaWeed Concept raises 2 million euros to expand production of seaweed for human consumption
SeaWeed Concept, start-up specializing in the use of lacto-fermented seaweed for human consumption, has just raised 2 million euros from the Paris-based Blue Forward Fund. This...
12 February 2025
Ekstere raises €2,4 million to make cycling truly sustainable !
Entry of Ekstere into the Sport and Performance Capital funds of Seventure Partners.
Structuring the second-hand bike market through listing.
Make sustainable...
6 February 2025
Anybuddy raises €2M with Seventure Partners’ Sport & Performance Capital fund and becomes the benchmark in racquet sports by accelerating its focus on padel.
Anybuddy, France's leading racquet sports booking platform, has announced a €2 million round of financing to support its expansion and enhance its service offering.
By...
30 January 2025
Tubulis Announces First Patient Dosed in Phase I/IIa Trial Evaluating ADC TUB-030 in Advanced Solid Tumors
Tubulis announced today that its second drug candidate, TUB-030, has entered clinical evaluation with successful dosing of the first patient in the 5-STAR 1-01 Phase I/IIa...
21 January 2025
MaaT Pharma Announces Positive Second DSMB Review of Ongoing Phase 2b Clinical Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT
MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated...
21 January 2025
Extending Insights to the Small Intestine: Cmbio™ Teams Up with Nimble Science
Cmbio™, a global leader in multi-omics science and digital biology, announces a strategic partnership with Nimble Science, to deliver first in class high-quality, multi-omic...